1. Poulsen A, Demeny AK, Bang Plum C, Gjerum Nielsen K, Schmiegelow K. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 2001; 37:20–23.
Article
2. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15:1143–1238.
Article
3. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001; 286:2450–2460.
Article
4. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004; 10:1713–1720.
5. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014; 10:Cd005590.
6. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIVinfected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82:1052–1059.
Article
7. Proudfoot R, Cox R, Phillips B, Wilne S. UK survey of Pneumocystis jirovecii pneumonia (PJP) prophylaxis use in paediatric oncology patients. Arch Dis Child. 2015; 100:115.
Article
8. Shankar SM, Nania JJ. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs. 2007; 9:301–309.
Article
9. Wang XL, Wang XL, Wei W. Retrospective study of Pneumocystis pneumonia over half a century in mainland China. J Med Microbiol. 2011; 60:631–638.
Article
10. Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006; 25:382–388.
Article
11. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002; 21:523–531.
Article
12. Kim SJ, Lee J, Cho YJ, Park YS, Lee CH, Yoon HI, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect. 2014; 69:88–95.
Article
13. Tamai K, Tachikawa R, Tomii K, Nagata K, Otsuka K, Nakagawa A, et al. Prognostic value of bronchoalveolar lavage in patients with non-HIV Pneumocystis pneumonia. Intern Med. 2014; 53:1113–1117.
Article
14. Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS. 2000; 14:2559–2566.
Article
15. World Health Organization: Programme for the Control of Acute Respiratory infections. Acute respiratory infection in children: case management in small hospitals in developing countries. A manual for doctors and other senior health workers. Geneva, Switzerland: World Health Organization;1990.
16. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005; 6:2–8.
Article
17. Zajac-Spychala O, Gowin E, Fichna P, Wysocki J, Fichna M, Kowala-Piaskowska A, et al. Pneumocystis pneumonia in children - the relevance of chemoprophylaxis in different groups of immunocompromised and immunocompetent paediatric patients. Cent Eur J Immunol. 2015; 40:91–95.
18. Saltzman RW, Albin S, Russo P, Sullivan KE. Clinical conditions associated with PCP in children. Pediatr Pulmonol. 2012; 47:510–516.
Article
19. Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother. 2014; 20:412–416.
Article
20. Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne RA, Cardeau-Desangles I, et al. Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transplant. 2015; 15:190–199.
Article
21. Laursen AL, Mogensen SC, Andersen HM, Andersen PL, Ellermann-Eriksen S. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii. Clin Exp Immunol. 2001; 123:239–246.
Article
22. Jensen AM, Lundgren JD, Benfield T, Nielsen TL, Vestbo J. Does cytomegalovirus predict a poor prognosis in Pneumocystis carinii pneumonia treated with corticosteroids? A note for caution. Chest. 1995; 108:411–414.
Article
23. Saah AJ, Hoover DR, Peng Y, Phair JP, Visscher B, Kingsley LA, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study. JAMA. 1995; 273:1197–1202.
Article
24. Nahimana A, Rabodonirina M, Zanetti G, Meneau I, Francioli P, Bille J, et al. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J Infect Dis. 2003; 188:1017–1023.
Article
25. Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev. 2015; 4:Cd006150.
Article
26. Moon SM, Kim T, Sung H, Kim MN, Kim SH, Choi SH, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother. 2011; 55:4613–4618.
Article
27. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998; 113:1215–1224.
Article
28. Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res. 2005; 25:651–655.
29. Guo F, Chen Y, Yang SL, Xia H, Li XW, Tong ZH. Pneumocystis pneumonia in HIV-infected and immunocompromised non-HIV infected patients: a retrospective study of two centers in China. PLoS One. 2014; 9:e101943.
Article
30. Gracia JD, Miravitlles M, Mayordomo C, Ferrer A, Alvarez A, Bravo C, et al. Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. Chest. 1997; 111:1180–1186.
Article
31. Leigh TR, Gazzard BG, Rowbottom A, Collins JV. Quantitative and qualitative comparison of DNA amplification by PCR with immunofluorescence staining for diagnosis of Pneumocystis carinii pneumonia. J Clin Pathol. 1993; 46:140–144.
Article
32. Colangelo G, Baughman RP, Dohn MN, Frame PT. Followup bronchoalveolar lavage in AIDS patients with Pneumocystis carinii pneumonia. Pneumocystis carinii burden predicts early relapse. Am Rev Respir Dis. 1991; 143:1067–1071.
Article